期刊文献+

甘肃回族藏族人群CYP2C19基因多态性分析 被引量:8

Genetic polymorphism analysis of cytochrome P450 2C19 in Chinese Hui and Zang populations of Gansu
暂未订购
导出
摘要 目的确定细胞色素P450 2C19(CYP2C19)在甘肃地区回族藏族人群中的基因型及等位基因分布特征,并考察性别对其基因多态性的影响。方法选取甘肃地区回族藏族无亲缘关系的健康人,采用多聚酶链反应-限制性片段长度多态性(PCR-RFLP)法分析CYP2C19基因多态性。结果检测到CYP2C19的5个基因型,其在男女间分布差异无统计学意义,但在回族藏族间分布差异有统计学意义(P<0.05)。结论在甘肃地区回族藏族健康人群中,CYP2C19的基因型分布差异有统计学意义,而性别对CYP2C19遗传多态性无显著影响。 Objective To identify the genotype and allele distribution feature of cytochrome P450 2C19(CYP2C19)in Chinese Hui and Zang populations of Gansu,and investigate the effects of gender on genetic polymorphism of CYP2C19 in the populations.Methods The CYP2C19 genotype of unrelated healthy Chinese Hui and Zang population subjects were assessed by polymerase chain reaction and restriction fragment length polymorphism(PCR-RFLP).Results Five different CYP2C19 genotypes were observed in this study.There was no significant difference between male and female,but significant difference between the two Chinese populations(P0.05).Conclusion Population has significant effect on genetic polymorphism of CYP2C19 in Chinese Hui and Zang populations of Gansu,and the effect on gender is not significant.
出处 《实用药物与临床》 CAS 2010年第2期95-97,共3页 Practical Pharmacy and Clinical Remedies
关键词 回族 藏族 细胞色素P450 2C19 基因多态性 多聚酶链反应-限制性片段长度多态性 Hui Zang CYP2C19 Genetic polymorphism PCR-RFLP
  • 相关文献

参考文献6

  • 1Wilkinson GR.Drug metabolism and variability among patients in drug response[J].N Engl J Med,2005,352 (21):2211-2221.
  • 2陈东燕,孙艳荪,乔珊,吴子刚.CYP2C19基因多态性对幽门螺杆菌感染酸相关性疾病治愈率的影响[J].实用医学杂志,2006,22(19):2324-2326. 被引量:7
  • 3Wang JF,Wei DQ,Chen C,et al.Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design[J].Protein Pept Lett,2008,15(1):27-32.
  • 4Nakamoto K,Kidd JR,Jenison RD,et al.Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips[J].Pharmacogenet Genomics,2007,17 (2):103-114.
  • 5Saraeva RB,Paskaleva ID,Doncheva E,et al.Pharmacogenetics of acenocoumarol:CYP2C9,CYP2C19,CYP1A2,CYP3A4,CYP3A5 and ABCB1 gene polymorphisms and dose requirements[J].J Clin Pharm Ther,2007,32 (6):641-649.
  • 6Pestka EL,Hale AM,Johnson BL,et al.Cytochrome P450 testing for better psychiatric care[J].J Psychosoc Nurs Ment Health Serv,2007,45(10):15-18.

二级参考文献28

  • 1牛春燕,罗金燕,王学勤,朱有玲.CYP2C19基因多态性对埃索美拉唑抑酸效应的影响[J].西安交通大学学报(医学版),2004,25(5):487-489. 被引量:13
  • 2姜英杰,李瑜元,聂玉强,王红,沙卫红.雷贝拉唑根除幽门螺杆菌疗效及其与CYP2C19基因多态性的关系[J].广州医学院学报,2004,32(3):22-25. 被引量:22
  • 3[2]DOJO M,AZUMA T,SAITO T,et al.Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole),amoxycillin and clarithromycin in Japan[J].Dig Liver Dis,2001,33(8):671 -675.
  • 4[3]SAGAR M,TYBRING G,DAHL M L,et al.Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism[J].Gastroenterology,2000,119(3):670-676.
  • 5[5]FURUTA T,SAGEHASHI Y,SHIRAI N,et al.Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection[J].Clin Gastroenterol Hepatol,2005,3(6):564-573.
  • 6[6]TOGAWA J,INAMORI M,FUJISAWA N,et al.Efficccy of a triple therapy with rabeprazole,amoxicillin,and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy[J].Hepatogastroenterology,2005,52 (62):645-648.
  • 7[7]SAITO M,YASUI-FURUKORI N,UNO T,et al.Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes[J].Br J Clin Pharmacol,2005,59(3):302-309.
  • 8[9]LEE S B,PARK S J,RYU J K,et al.Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype[J].Korean J Gastroenterol,2003,42 (6):468-475.
  • 9[13]SCHWAB M,KLOTZ U,HOFMANN U,et al.Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19:evidence from clinical and pharmacokinetic data[J].Clin Pharmacol Ther,2005,78 (6):627-634.
  • 10[14]SHEU B S,KAO A W,CHENG H C,et al.Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism[J].Aliment Pharmacol Ther,2005,21 (3):283-288.

共引文献6

同被引文献78

引证文献8

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部